Company intelligence / Profile preview

Cyclacel Pharmaceuticals, Inc.

Berkeley Heights, New Jersey, United Statescyclacel.com ↗

Ownership: Public · CYCC
Employees: ~18
Development stage: Other

Overview

Cyclacel is a clinical-stage biopharmaceutical company developing small molecule drugs targeting cell cycle control mechanisms in cancer. Its lead program, fadraciclib (CDK2/9 inhibitor), is in mid-stage clinical trials with encouraging early safety and efficacy data in biomarker-selected patients with advanced solid tumors. Plogosertib (PLK1 inhibitor) is also in mid-stage development. The pipeline includes additional assets at earlier stages or discontinued due to trial results.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Partnerships

Collaborations with major academic centers including MD Anderson Cancer Center and Dana Farber Cancer Institute to enhance clinical programs.

Beyond the preview

Go deeper on Cyclacel Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclacel Pharmaceuticals, Inc..